Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Metastatic breast cancer (MBC) is generally incurable. However, 10–20-year relapse-free survival of MBC is approximately 2%, implying that at least a small subset of MBC patients achieve prolonged survival. We therefore analyzed long-term outcome in a particular subset, i.e., oligometastatic breast cancer (OMBC).
Data of OMBC subjects (N = 75) treated in our institution from April 1980 to March 2010 were retrospectively analyzed. OMBC was identified as: one or 2 organs involved with metastatic lesions (excluding the primary lesion resectable by surgery), fewer than 5 lesions per metastasized organ, and lesion diameter less than 5 cm. Patients were generally treated with systemic chemotherapy first, and those who achieved complete response (CR) or partial response (PR) were further treated, if applicable, with local therapy (surgical or radiation therapy) to maintain CR or to induce no evidence of clinical disease (NED), with additional systemic therapy.
Median follow-up duration was 103 (6–329) months. Single or 2 organs were involved in, respectively, 44 (59%) and 31 (41%) cases with metastatic lesions, 48% of which were visceral. In cases where effects of systemic therapy, possibly in combination with other treatments, were evaluated (N = 68), CR or PR was achieved in 33 (48.5%) or 32 (47.1%), respectively, with overall response rate (ORR: CR + PR) of 95.6% (N = 65). In cases receiving multidisciplinary treatment (N = 75), CR or NED (CR/NED), or PR was induced in 48 (64.0%) or 23 (30.7%) cases, respectively, with ORR (CR/NED + PR) of 94.7% (N = 71). CR rates (60.5%) with systemic therapy and CR/NED rates (79.5%) with multidisciplinary treatment were significantly better in subjects with a single involved organ than in those with two involved organs (P = 0.047 and 0.002, systemic only or multidisciplinary treatments, respectively).
Medians estimated by Kaplan–Meier method were: overall survival (OS) of 185.0 months and relapse-free interval (RFI) of 48.0 months. Estimated outcomes were: OS rates (OSR) of 59.2% at 10 years and 34.1% at 20 years, and relapse-free rates (RFR) of 27.4% at 10 years and 20 years. No disease progression was observed after 101.0 months as RFR. Cases with single organ involvement (N = 44) showed significantly better outcomes (OSR of 73% at 10 years and 52% at 20 years, RFR of 42% at 10 years and 20 years). Those who received local therapies (N = 35) also showed better prognosis: OSR of 82% at 10 years and 53% at 20 years, RFR of 38% at 10 years and 20 years. Three cases (4%) survived for their lifetime without relapse after achieving CR or NED, our definition of clinical cure.
Multivariate analysis revealed factors favoring better prognosis as: none for OS, and single organ involvement with metastasis, administration of local treatment, and shorter disease-free interval (DFI) (P = 0.030, 0.039, and 0.042, respectively) for RFR. Outcomes in OMBC in literature were OSR of 35–73% at 10 years and 26–52% at 20 years, and RFR of 27–42% at 10 years and 26–42% at 20 years.
The present analyses clearly indicate that OMBC is a distinct subgroup with long-term prognosis superior to MBC, with reasonable provability for clinical cure. Further prospective studies to better characterize OMBC are warranted to improve prognosis in MBC.
- Tan S-H, Wolff AC. Treatment of metastatic breast cancer: chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 877–919.
- Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–63. CrossRef
- Hayes DF. General principles of management of metastatic breast cancer. Up To Date. 2010; version 18.3.
- Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20:620–3.
- Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31:S149–61. CrossRef
- Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.
- Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44–52. CrossRef
- Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9. CrossRef
- Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100:1780–91. CrossRef
- Fentiman IS, Cuzick J, Millis RR, Hayward JL. Which patients are cured of breast cancer? Br Med J (Clin Res Ed). 1984;289:1108–11. CrossRef
- Güth U, Huang DJ, Dirnhofer S, Rochlitz C, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15:81–6. CrossRef
- Wood WC. Breast surgery in advanced breast cancer: local control in the presence of metastases. Breast. 2007;16:S63–6. CrossRef
- Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds) Cancer, 8th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 1606–54.
- Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979;39:1552–62.
- Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer. 1999;85:104–11. CrossRef
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
- Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104:1158–71. CrossRef
- Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974–84. CrossRef
- WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva: WHO; 1979.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16. CrossRef
- Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50. CrossRef
- Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800. CrossRef
- Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer. 1996;32A:1876–87. CrossRef
- Babiera GV. Metastatic breast cancer: a paradigm shift toward a more aggressive approach. Cancer J. 2009;15:78. CrossRef
- Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894;20:497–555. CrossRef
- Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1–19. CrossRef
- Fisher B. Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863–74.
- Hellman S. Natural history of small breast cancers. J Clin Oncol. 1994;12:2229–34.
- Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 1964;35:1–111.
- Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–33.
- Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist. 2005;10:370–81. CrossRef
- Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007;7:471–9. CrossRef
- Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol. 1994;12:2071–7.
- Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, et al. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997;3:2633–7.
- Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707–18. CrossRef
- Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002;8:2–9. CrossRef
- Rauschecker H, Clarke M, Gatzemeier W, Recht A. Systemic therapy for treating locoregional recurrence in women with breast cancer. The Cochrane Library. 2008; (Issue 4). Review. doi:10.1002/14651858.CD002195.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology-Breast Cancer Version 2. 2011. http://www.nccn.com. Accessed 2 Aug 2011.
- Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008;15:3384–95. CrossRef
- Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, et al. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27–02, BIG 1–02, and NSABP B-37. Clin Breast Cancer. 2008;8:287–92. CrossRef
- Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast. 2007;16:9–10. CrossRef
- Wolff AC. Systemic therapy. Curr Opin Oncol. 2002;14:600–8. CrossRef
- Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr. 1986;1:87–94.
- The French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19:602–11.
- Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253–9. CrossRef
- Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83. CrossRef
- Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission. Cancer. 2007;110:2756–60. CrossRef
- Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–907. CrossRef
- Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154–63. CrossRef
- Crosby WH. To treat or not to treat acute granulocytic leukemia. Arch Intern Med. 1968;122:79–80. CrossRef
- Boggs DR, Wintrobe MM, Cartwright GE. To treat or not to treat acute granulocytic leukemia. II. Arch Intern Med. 1969;123:568–70. CrossRef
- Crosby WH. Grounds for optimism in treating acute granulocytic leukemia. Arch Intern Med. 1974;134:177–80. CrossRef
- Yamamoto N, Katsumata N, Watanabe T, Omuro Y, Ando M, Narabayashi M, et al. Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Jpn J Clin Oncol. 1998;28:368–73. CrossRef
- Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review
Volume 19, Issue 3 , pp 218-237
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Oligometastatic breast cancer
- Metastatic breast cancer
- Relapse-free survival
- Clinical cure
- Industry Sectors
- Tadashi Kobayashi (1)
- Tamotsu Ichiba (1)
- Toshikazu Sakuyama (1)
- Yasuhiro Arakawa (1)
- Eijiroh Nagasaki (1)
- Keisuke Aiba (1)
- Hiroko Nogi (2)
- Kazumi Kawase (2)
- Hiroshi Takeyama (2)
- Yasuo Toriumi (2)
- Ken Uchida (2)
- Masao Kobayashi (3)
- Chihiro Kanehira (3)
- Masafumi Suzuki (4)
- Naomi Ando (5)
- Kazuhiko Natori (6)
- Yasunobu Kuraishi (6)
- Author Affiliations
- 1. Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 2. Department of Breast and Endocrine Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 3. Department of Therapeutic Radiology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 4. Department of Pathology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 5. Department of Pharmacology, The Jikei University Hospital, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
- 6. Department of Hematology and Oncology, Toho University Omori Medical Center, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan